Daisuke Sakai

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

Yukinori Kurokawa, Naotoshi Sugimoto, Hiroto Miwa et al. · British Journal of Cancer · 2014 · 140 citations · Full text

Medicine, Oncology, Pharmacology +12

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa et al. · Journal of Clinical Oncology · 2022 · 119 citations · Full text

Medicine, Oncology, Pharmacology +16

Aldehyde dehydrogenasehigh gastric cancer stem cells are resistant to chemotherapy

Shimpei Nishikawa, Masamitsu Konno, Atsushi Hamabe et al. · International Journal of Oncology · 2013 · 108 citations · Full text

Medicine, Cell Biology, Oncology +16